Radioelectric brain stimulation in the treatment of generalized anxiety disorder with comorbid major depression in a psychiatric hospital: A pilot study

Neuropsychiatric Disease and Treatment

Volumn 7, Issue 1, 2011, Pages 449-455

  Olivieri, Elisabetta Bourget ^a   Vecchiato, Caterina ^a   Ignaccolo, Nunziatina ^a   Mannu, Piero ^b   Castagna, Alessandro ^b   Aravagli, Lucia ^b   Fontani, Vania ^b   Rinaldi, Salvatore ^b,c  

^a Trust S Croce and Carle Complex   (Italy)

^b Rinaldi Fontani Institute   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Anxiety disorders; Depressive disorder; Psychiatric somatic therapies; Radioelectric asymmetric brain stimulation

Indexed keywords

SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; BRAIN DEPTH STIMULATION; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEVICE SAFETY; ELECTRICAL EQUIPMENT; FEMALE; GENERALIZED ANXIETY DISORDER; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; MENTAL HOSPITAL; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PILOT STUDY; RADIOELECTRIC ASYMMETRIC CONVEYER; RADIOELECTRIC BRAIN STIMULATION; SCORING SYSTEM; SYMPTOM CHECKLIST 90; TREATMENT RESPONSE;

EID: 79961030373     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Baldwin DS, Ajel KI, Garner M. Pharmacological treatment of generalized anxiety disorder. Curr Top Behav Neurosci. 2010;2: 453-467.
2. Mackenzie CS, Reynolds K, Chou KL, Pagura J, Sareen J. Prevalence and correlates of generalized anxiety disorder in a national sample of older adults. Am J Geriatr Psychiatry. 2011;19:305-315.
3. Michelson SE, Lee JK, Orsillo SM, Roemer L. The role of values - consistent behavior in generalized anxiety disorder. Depress Anxiety. 2011;28:358-366.
4. Newman MG, Llera SJ. A novel theory of experiential avoidance in generalized anxiety disorder: a review and synthesis of research supporting a contrast avoidance model of worry. Clin Psychol Rev. 2011;31: 371-382.
5. Bruce TJ, Saeed SA. Social anxiety disorder: a common, underrecognized mental disorder. Am Fam Physician. 1999;60:2311-20.
6. el-Miedany YM, el-Rasheed AH. Is anxiety a more common disorder than depression in rheumatoid arthritis? Joint Bone Spine. 2002;69: 300-306.
7. Zamorski MA, Ward RK. Social anxiety disorder: common, disabling, and treatable. J Am Board Fam Pract. 2000;13:251-260.
8. Goncalves DC, Pachana NA, Byrne GJ. Prevalence and correlates of generalized anxiety disorder among older adults in the Australian National Survey of Mental Health and Well-Being. J Affect Disord.2011;132:223-230.
9. Blondeau J, Bouvette A. Generalized anxiety disorder: recognizing it and understanding its impact on the cognitive functioning. Sante Ment Que. 2010;35:221-245. French.
10. Cravello L, Caltagirone C, Spalletta G. The SNRI venlafaxine improves emotional unawareness in patients with post-stroke depression. Hum Psychopharmacol. 2009;24:331-336.
11. Sclar DA, Robison LM, Skaer TL. Concomitant triptan and SSRI or SNRI use: a risk for serotonin syndrome. Headache. 2008;48:126-129.
12. Vlahiotis A, Devine ST, Eichholz J, Kautzner A. Discontinuation rates and health care costs in adult patients starting generic versus brand SSRI or SNRI antidepressants in commercial health plans. J Manag Care Pharm. 2011;17:123-132.
13. Bitran S, Farabaugh AH, Ameral VE, et al. Do early changes in the HAM-D-17 anxiety/somatization factor items affect the treatment outcome among depressed outpatients? Comparison of two controlled trials of St John's wort (Hypericum perforatum) versus a SSRI. Int Clin Psychopharmacol. 2011;26:206-212.
14. Haliburn J. Adolescent suicide and SSRI antidepressants. Australas Psychiatry. 2010;18:587.
15. McCabe C, Mishor Z, Filippini N, Cowen PJ, Taylor MJ, Harmer CJ. SSRI administration reduces resting state functional connectivity in dorso-medial prefrontal cortex. Mol Psychiatry. 2011;16:592-594.
16. Rucci P, Frank E, Scocco P, et al. Treatment-emergent suicidal ideation during 4 months of acute management of unipolar major depression with SSRI pharmacotherapy or interpersonal psychotherapy in a randomized clinical trial. Depress Anxiety. 2011;28:303-309.
17. Sansone RA, Sansone LA. SSRI-induced indifference. Psychiatry (Edgmont). 2010;7:14-18.
18. Silver H, Susser E, Danovich L, et al. SSRI augmentation of antipsychotic alters expression of GABA(A) receptor and related genes in PMC of schizophrenia patients. Int J Neuropsychopharmacol. 2011;14: 573-584.
19. Gosselin P, Ladouceur R, Morin CM, Dugas MJ, Baillargeon L. Benzodiazepine discontinuation among adults with GAD: a randomized trial of cognitive-behavioral therapy. J Consult Clin Psychol. 2006;74: 908-919.
20. Ladouceur R, Leger E, Dugas M, Freeston MH. Cognitive-behavioral treatment of generalized anxiety disorder (GAD) for older adults. Int Psychogeriatr. 2004;16:195-207.
21. Gaudiano BA. Review: cognitive behavioural therapy is an effective treatment for depression, panic disorder, and generalised anxiety disorder, but may be less effective in severe cases. Evid Based Ment Health. 2006;9:80.
22. Haby MM, Donnelly M, Corry J, Vos T. Cognitive behavioural therapy for depression, panic disorder and generalized anxiety disorder: a meta- regression of factors that may predict outcome. Aust N Z J Psychiatry. 2006;40:9-19.
23. Proudfoot J, Ryden C, Everitt B, et al. Clinical efficacy of computerised cognitive-behavioural therapy for anxiety and depression in primary care: randomised controlled trial. Br J Psychiatry. 2004;185:46-54.
24. Davidson JR, Feltner DE, Dugar A. Management of generalized anxiety disorder in primary care: identifying the challenges and unmet needs. Prim Care Companion J Clin Psychiatry. 2010:12(2).
25. Rinaldi S, Fontani V, inventors; Rinaldi S, Fontani V, assignees. Radioelectric asymmetric conveyer for therapeutic use. US patent EP1301241 (B1). October 11, 2006.
26. Rinaldi S., Fontani V, inventors; Rinaldi S, Fontani V, assignees. Radioelectric asymmetric conveyer for therapeutic use. US patent 7,333,8592001.
27. Castagna A, Rinaldi S, Fontani V, Mannu P. Radioelectric asymmetric brain stimulation and lingual apex repositioning in patients with atypical deglutition. 2011;4:209-213.
28. Castagna A, Rinaldi S, Fontani V, Aravagli L, Mannu P, Margotti ML. Does osteoarthritis of the knee also have a psychogenic component? Psycho-emotional treatment with a radio-electric device vs intraarticular injection of sodium hyaluronate: an open-label, naturalistic study. Acupunct Electrother Res. 2010;35:1-16.
29. Collodel G, Moretti E, Fontani V, et al. Effect of emotional stress on sperm quality. Indian J Med Res. 2008;128:254-261.
30. Mannu P, Rinaldi S, Fontani V, Castagna A, Lotti Margotti M. Radio electric treatment vs es-citalopram in the treatment of panic disorders associated with major depression: an open-label, naturalistic study. Acupunct Electrother Res. 2009;34:135-149.
31. Rinaldi S, Fontani V, Aravagli L, Margotti ML. Psychological and symptomatic stress-related disorders with radio-electric treatment: psychometric evaluation. Stress and Health. 2010;26(5):350-358.
32. Rinaldi S, Fontani V, Aravagli L, Mannu P. Psychometric evaluation of a radio electric auricular treatment for stress related disorders: a double-blinded, placebo-controlled controlled pilot study. Health Qual Life Outcomes. 2010;8:31.
33. Rinaldi S, Fontani V, Moretti E, et al. A new approach on stress-related depression and anxiety: neuro-psycho-physical-optimization with radio electric asymmetric conveyer. Indian J Med Res. 2010;132: 189-194.
34. Mannu P, Rinaldi S, Fontani V, Castagna A. Long-term treatment of bipolar disorder with a radioelectric asymmetric conveyor. Neuropsychiatr Dis Treat. 2011;7:373-379.
35. Pedersen G, Karterud S. Is SCL-90R helpful for the clinician in assessing DSM-IV symptom disorders? Acta Psychiatr Scand. 2004;110: 215-224.
36. Olsen LR, Mortensen EL, Bech P. The SCL-90 and SCL-90R versions validated by item response models in a Danish community sample. Acta Psychiatr Scand. 2004;110:225-229.
37. Serrano-Duenas M, Soledad Serrano M. Concurrent validation of the 21-item and 6-item Hamilton Depression Rating Scale versus the DSM-IV diagnostic criteria to assess depression in patients with Parkinson's disease: an exploratory analysis. Parkinsonism Relat Disord. 2008;14:233-238.
38. Kadouri A, Corruble E, Falissard B. The improved Clinical Global Impression Scale (iCGI): development and validation in depression. BMC Psychiatry. 2007;7:7.
39. Tadic A, Wagner S, Gorbulev S, et al. Peripheral blood and neuropsychological markers for the onset of action of antidepressant drugs in patients with major depressive disorder. BMC Psychiatry. 2011; 11:16.
40. Carver CS, Johnson SL, Joormann J. Serotonergic function, two- mode models of self-regulation, and vulnerability to depression: what depression has in common with impulsive aggression. Psychol Bull. 2008;134:912-943.
41. Bennett JA, Moioffer M, Stanton SP, Dwight M, Keck PE Jr. A riskbenefit assessment of pharmacological treatments for panic disorder. Drug Saf. 1998;18:419-430.
42. Sinclair LI, Christmas DM, Hood SD, et al. Antidepressant-induced jitteriness/anxiety syndrome: systematic review. Br J Psychiatry. 2009; 194:483-490.
43. Byrd L. Serotonin syndrome: what is it? causes, recognition, and management. Geriatr Nurs. 2010;31:387-389.
44. Coster S, Visser MH, Touw DJ, Wirtz PW. Serotonin syndrome with sertraline and indomethacin. J Clin Psychopharmacol. 2010;30: 468-470.
45. Evans RW, Tepper SJ, Shapiro RE, Sun-Edelstein C, Tietjen GE. The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin- norepinephrine reuptake inhibitors: American Headache Society position paper. Headache. 2010;50:1089-1099.
46. Lawyer TI, Jensen J, Welton RS. Serotonin syndrome in the deployed setting. Mil Med. 2010;175:950-952.
47. Peacock LE, Wright F. Serotonin syndrome secondary to tramadol and citalopram. Age Ageing. 2011;40:528.
48. Rothrock JF. Triptans, SSRIs/SNRIs and serotonin syndrome. Headache.2010;50:1101-1102.
49. Sanyal D, Chakraborty S, Bhattacharyya R. An interesting case of serotonin syndrome precipitated by escitalopram. Indian J Pharmacol. 2010;42:418-419.
50. Rockstroh BS, Wienbruch C, Ray WJ, Elbert T. Abnormal oscillatory brain dynamics in schizophrenia: a sign of deviant communication in neural network? BMC Psychiatry. 2007;7:44.
51. Rissling AJ, Makeig S, Braff DL, Light GA. Neurophysiologic markers of abnormal brain activity in schizophrenia. Curr Psychiatry Rep. 2010; 12:572-578.
52. Kirby ED, Friedman AR, Covarrubias D, et al. Basolateral amygdala regulation of adult hippocampal neurogenesis and fear-related activation of newborn neurons. Mol Psychiatry. June 14, 2011. [Epub ahead of print.]